



CLINUVEL'S GROWTH AND EXPANSION

Building a Specialty Pharmaceutical Group

Wilsons Rapid Insights Conference
25 November 2021

CLINUVEL Group
ASX:
Level 1 ADR (Nasdaq Int'l Designation):
XETRA-DAX:

CUV
CLVLY
UR9

clinuvel.com
news.clinuvel.com

Presented by:

Malcolm Bull

Head of Investor Relations

Legal Notice

This release contains forward-looking statements, which reflect the current beliefs and intentions of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, achievements or output to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents, trademark and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and

reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; risks originating from equity markets, and other factors that have been discussed in our 2021 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new material information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Building a Specialty Pharmaceutical Group

Key Talking Points

1. Vision
2. Key Success Factors
3. Operational and Financial Update
4. Multi-Pronged Strategy
 - Targeted Technology Translation
5. Portfolio of Melanocortins
6. Clinical Development
7. Healthcare Solutions
8. Planning 2022 and Beyond



Thank You

For Your Attention

CLINUVEL Group
ASX:
Level 1 ADR (Nasdaq Int'l Designation):
XETRA-DAX:

CUV
CLVLY
UR9

clinovel.com
news.clinovel.com

Presented by

Malcolm Bull

Head of Investor Relations